Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ MAGEB2 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA584954
Description
Immunogen sequence: RDETRGLNVP QVTEAEEEEA PCCSSSVSGG AASSSPAAGI P.
MAGEB2 is a member of the MAGEB gene family. The members of this family have their entire coding sequences located in the last exon, and the encoded proteins show 50 to 68% sequence identity to each other. The promoters and first exons of the MAGEB genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. This gene is localized in the DSS (dosage-sensitive sex reversal) critical region. It is expressed in testis and placenta, and in a significant fraction of tumors of various histological types. The MAGEB genes are clustered on chromosome Xp22-p21.
Specifications
MAGEB2 | |
Polyclonal | |
Unconjugated | |
MAGEB2 | |
Cancer/testis antigen 3.2; cancer/testis antigen family 3, member 2; CT3.2; DAM6; DSS/AHC critical interval MAGE superfamily 6; DSS-AHC critical interval MAGE superfamily 6; MAGE family member B2; MAGE XP-2 antigen; MAGEB2; MAGE-B2 antigen; MAGE-XP-2; melanoma antigen family B, 2; melanoma antigen family B2; melanoma-associated antigen B2; MGC26438 | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
4113 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Immunohistochemistry (Paraffin) | |
0.10 mg/mL | |
PBS with 40% glycerol and 0.02% sodium azide; pH 7.2 | |
O15479 | |
MAGEB2 | |
Recombinant protein corresponding to Human MAGEB2. Recombinant protein control fragment (Product #RP-108267). | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction